De novo glomerulonephritis

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

De novo dyspareunia occurred in 17 of 445 (3.8%) women who were sexually active without pain at baseline. Only 1 of the 17 (6%) women who experienced de novo dyspareunia had a mesh or graft augmented

Effect: adverse; 3.8% (17/445)

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months

Among women without baseline dyspareunia (n=134), 6%, 5%, and 10% reported de novo dyspareunia at 6, 12, and 24 months respectively. Only 3 of 19 affected women received treatment by 24 months, and no

Effect: adverse; 10% de novo dyspareunia at 24 months